Form 4: Biote Corp. Director Richard Barrera Receives Option Grant

Director Richard R. Barrera was granted 121,452 stock options in Biote Corp. with an exercise price of $2.20.

Summary

• Director Richard R. Barrera received a grant of 121,452 stock options to purchase Class A Common Stock.
• The options have an exercise price of $2.20 per share.
• The grant date for the options is May 12, 2026.
• The options are set to expire on May 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is contingent upon the reporting person's continuous service through the vesting date.

Future Outlook

The options vest on the earlier of May 12, 2027, or the day prior to the 2027 Annual Meeting of Stockholders, provided the director remains in continuous service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure leadership remains incentivized to drive long-term company performance in the biotechnology and hormone optimization sector.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard compensation practices for publicly traded small-cap companies.
• The 10-year expiration term is a standard industry benchmark for executive and director stock option plans.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 12, 2027, or the day prior to the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Biote Corp, BTMD, Director Compensation, Stock Options, Insider Transaction, SEC Form 4